Generalized epilepsy with febrile seizures plus: Difference between revisions
CSV import |
|||
| Line 17: | Line 17: | ||
=== GABRG2 === | === GABRG2 === | ||
The [[GABRG2]] gene encodes a subunit of the GABA_A receptor, which is involved in inhibitory neurotransmission. Mutations in this gene can disrupt normal neuronal inhibition, contributing to the development of seizures. | The [[GABRG2]] gene encodes a subunit of the GABA_A receptor, which is involved in inhibitory neurotransmission. Mutations in this gene can disrupt normal neuronal inhibition, contributing to the development of seizures. | ||
Revision as of 21:15, 21 February 2025
Generalized Epilepsy with Febrile Seizures Plus
Generalized Epilepsy with Febrile Seizures Plus (GEFS+) is a familial epilepsy syndrome characterized by a spectrum of seizure types, including febrile seizures and afebrile generalized seizures. It is a genetic disorder that affects the nervous system, often beginning in infancy or early childhood.
Clinical Features
GEFS+ is marked by a variety of seizure types. The most common are febrile seizures, which are convulsions triggered by fever in young children. In addition to febrile seizures, individuals with GEFS+ may experience other types of seizures, such as absence seizures, myoclonic seizures, and tonic-clonic seizures.
Genetics
GEFS+ is primarily caused by mutations in genes that encode for ion channels, which are crucial for the proper functioning of neurons. The most commonly affected genes include:
SCN1A
The SCN1A gene encodes the alpha subunit of the voltage-gated sodium channel. Mutations in this gene are a major cause of GEFS+ and are also associated with more severe epilepsy syndromes such as Dravet syndrome.
SCN2A
The SCN2A gene encodes another subunit of the sodium channel. Mutations in SCN2A can lead to a range of epilepsy phenotypes, including GEFS+.
GABRG2
The GABRG2 gene encodes a subunit of the GABA_A receptor, which is involved in inhibitory neurotransmission. Mutations in this gene can disrupt normal neuronal inhibition, contributing to the development of seizures.
SCN1B
The SCN1B gene encodes the beta subunit of the sodium channel. Mutations in SCN1B can alter the function of sodium channels, leading to increased neuronal excitability and seizures.
Diagnosis
The diagnosis of GEFS+ is based on clinical evaluation, family history, and genetic testing. Genetic testing can identify mutations in the genes associated with the syndrome, confirming the diagnosis.
Treatment
Treatment for GEFS+ typically involves the use of antiepileptic drugs (AEDs) to control seizures. The choice of medication depends on the specific types of seizures experienced by the individual. In some cases, lifestyle modifications and avoidance of seizure triggers may also be recommended.
Prognosis
The prognosis for individuals with GEFS+ varies. Some individuals may outgrow their seizures, while others may continue to experience seizures into adulthood. The severity of the condition can also vary widely among affected individuals.
